{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:48:47Z","timestamp":1788965327201,"version":"build-2803163510"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p><jats:italic>HER2<\/jats:italic> amplification\/overexpression is a common driver in a variety of cancers including gallbladder cancer (GBC). For patients with metastatic GBC, chemotherapy remains the standard of care with limited efficacy. The combination of HER2 antibody trastuzumab plus chemotherapy is the frontline treatment option for patients with HER2-positive breast cancer and gastric cancer. Recently, this regime also showed antitumor activity in HER2-positive GBC. However, resistance to this regime represents a clinical challenge. Camrelizumab is a novel PD-1 antibody approved for Hodgkin lymphoma and hepatocellular carcinoma in China. In this study, we presented a HER2-positive metastatic GBC patient who was refractory to trastuzumab plus chemotherapy but experienced significant clinical benefit after the addition of camrelizumab. Our case highlights the potential of immunotherapy in combination with HER2-targeted therapy in HER2-positive GBC. We also demonstrated that two immune-related adverse events (irAEs) associated with camrelizumab can be managed with an anti-VEGF agent apatinib. This case not only highlights the importance of irAE management in patients treated with camrelizumab, but also demonstrates the potential of PD-1 antibody plus trastuzumab in HER2-positive GBC patients who have developed resistance to chemotherapy and trastuzumab-based targeted therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2021.784861","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T05:24:30Z","timestamp":1641446670000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient"],"prefix":"10.3389","volume":"12","author":[{"given":"Li","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonghui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33476","article-title":"The Global, Regional, and National Burden of Gallbladder and Biliary Tract Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study 2017","volume":"127","author":"Ouyang","year":"2021","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00153-7","article-title":"Biliary Tract Cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet (London England)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.266","article-title":"Final Results From ClarIDHy, a Global, Phase III, Randomized, Double-Blind Study of Ivosidenib (IVO) Versus Placebo (PBO) in Patients (Pts) With Previously Treated Cholangiocarcinoma (CCA) and an Isocitrate Dehydrogenase 1 (IDH1) Mutation","volume":"39","author":"Zhu","year":"2021","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.033","article-title":"Integrative Molecular Characterisation of Gallbladder Cancer Reveals Micro-Environment-Associated Subtypes","volume":"74","author":"Nepal","year":"2021","journal-title":"J Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7150\/thno.56539","article-title":"Mutational Spectrum and Precision Oncology for Biliary Tract Carcinoma","volume":"11","author":"Lin","year":"2021","journal-title":"Theranostics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.19.00223","article-title":"Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine","volume":"3","author":"Mondaca","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-Targeted Therapies - a Role Beyond Breast Cancer. Nature reviews","volume":"17","author":"Oh","year":"2020","journal-title":"Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30812-x","article-title":"Pembrolizumab Plus Trastuzumab in Trastuzumab-Resistant, Advanced, HER2-Positive Breast Cancer (PANACEA): A Single-Arm, Multicentre, Phase 1b-2 Trial","volume":"20","author":"Loi","year":"2019","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4013","article-title":"Pembrolizumab Plus Trastuzumab and Chemotherapy for HER2+ Metastatic Gastric or Gastroesophageal Junction (G\/GEJ) Cancer: Initial Findings of the Global Phase 3 KEYNOTE-811 Study","volume":"39","author":"Janjigian","year":"2021","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-05-1692","article-title":"Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma","volume":"12","author":"Leone","year":"2006","journal-title":"Clin Cancer Res  Off J Am Assoc Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1158\/2159-8290.Cd-18-0598","article-title":"EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer","volume":"9","author":"Sanchez-Vega","year":"2019","journal-title":"Cancer Discov"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4079","article-title":"Pembrolizumab (Pembro) for Advanced Biliary Adenocarcinoma: Results From the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) Basket Studies","volume":"37","author":"Bang","year":"2019","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.4_suppl.62","article-title":"First-Line Pembrolizumab (P), Trastuzumab (T), Capecitabine (C) and Oxaliplatin (O) in HER2-Positive Metastatic Esophagogastric Adenocarcinoma (mEGA)","volume":"37","author":"Janjigian","year":"2019","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2018.0172","article-title":"Reactive Capillary Hemangiomas: A Novel Dermatologic Toxicity Following Anti-PD-1 Treatment With SHR-1210","volume":"16","author":"Chen","year":"2019","journal-title":"Cancer Biol Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-1680","article-title":"Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.63.5995","article-title":"Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-2484","article-title":"Anti-PD-1 Antibody SHR-1210 Combined With Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-Label, Dose Escalation and Expansion Study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-17-0640","article-title":"Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1\/PD-L1 Blockade in Lung Cancer","volume":"7","author":"Zhao","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.9112","article-title":"Efficacy of PD-1 Monoclonal Antibody SHR-1210 Plus Apatinib in Patients With Advanced Nonsquamous NSCLC With Wild-Type EGFR and ALK","volume":"37","author":"Zhou","year":"2019","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-17-0245","article-title":"New Horizons for Precision Medicine in Biliary Tract Cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"B22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/clep.S37357","article-title":"Gallbladder Cancer: Epidemiology and Outcome","volume":"6","author":"Hundal","year":"2014","journal-title":"Clin Epidemiol"},{"key":"B23","article-title":"Overexpression of the HER2\/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer","volume":"7","author":"Roa","year":"2014","journal-title":"Gastrointestinal Cancer Res GCR"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0922","article-title":"HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer","volume":"25","author":"Vivaldi","year":"2020","journal-title":"Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.humpath.2020.08.006","article-title":"Details of Human Epidermal Growth Factor Receptor 2 Status in 454 Cases of Biliary Tract Cancer","volume":"105","author":"Hiraoka","year":"2020","journal-title":"Hum Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02510","article-title":"Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update","volume":"39","author":"Denduluri","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0023","article-title":"NCCN Guidelines\u00ae Insights: Breast Cancer, Version 4.2021","volume":"19","author":"Gradishar","year":"2021","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00492-2","article-title":"Biomarker-Targeted Therapies for Advanced-Stage Gastric and Gastro-Oesophageal Junction Cancers: An Emerging Paradigm","volume":"18","author":"Nakamura","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-0927-7","article-title":"A Phase II Study of Lapatinib in Patients With Advanced Biliary Tree and Hepatocellular Cancer","volume":"64","author":"Ramanathan","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1159\/000336488","article-title":"HER2\/neu may Not be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study With Lapatinib","volume":"82","author":"Peck","year":"2012","journal-title":"Oncology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.320","article-title":"Targeting HER2 (ERBB2) Mutation-Positive Advanced Biliary Tract Cancers With Neratinib: Results From the Phase II SUMMIT \u2018Basket\u2019 Trial","volume":"39","author":"Harding","year":"2021","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00336-3","article-title":"Pertuzumab and Trastuzumab for HER2-Positive, Metastatic Biliary Tract Cancer (MyPathway): A Multicentre, Open-Label, Phase 2a, Multiple Basket Study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1158\/2159-8290.Cd-19-1014","article-title":"Targeting HER2 With Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30326-0","article-title":"Margetuximab Plus Pembrolizumab in Patients With Previously Treated, HER2-Positive Gastro-Oesophageal Adenocarcinoma (CP-MGAH22-05): A Single-Arm, Phase 1b-2 Trial","volume":"21","author":"Catenacci","year":"2020","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30169-8","article-title":"First-Line Pembrolizumab and Trastuzumab in HER2-Positive Oesophageal, Gastric, or Gastro-Oesophageal Junction Cancer: An Open-Label, Single-Arm, Phase 2 Trial","volume":"21","author":"Janjigian","year":"2020","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a Biomarker of Response to Immune-Checkpoint Inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30445-9","article-title":"Association of Tumour Mutational Burden With Outcomes in Patients With Advanced Solid Tumours Treated With Pembrolizumab: Prospective Biomarker Analysis of the Multicohort, Open-Label, Phase 2 KEYNOTE-158 Study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-20-0522","article-title":"Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High Tumor Mutation Burden Fails to Predict Immune Checkpoint Blockade Response Across All Cancer Types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2031965","article-title":"The Spectrum of Benefit From Checkpoint Blockade in Hypermutated Tumors","volume":"384","author":"Rousseau","year":"2021","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30110-8","article-title":"Camrelizumab Versus Investigator's Choice of Chemotherapy as Second-Line Therapy for Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (ESCORT): A Multicentre, Randomised, Open-Label, Phase 3 Study","volume":"21","author":"Huang","year":"2020","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(20)30365-9","article-title":"Camrelizumab Plus Carboplatin and Pemetrexed Versus Chemotherapy Alone in Chemotherapy-Naive Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer (CameL): A Randomised, Open-Label, Multicentre, Phase 3 Trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00302-8","article-title":"Camrelizumab Versus Placebo in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN-1st): A Multicentre, Randomised, Double-Blind, Phase 3 Trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1009-0460.2020.09.012","article-title":"Expert Consensus on the Clinical Diagnosis and Treatment of Reactive Skin Capillary Hyperplasia Caused by Camrelizumab","volume":"25","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_997_19","article-title":"Salvage Therapy of Reactive Capillary Hemangiomas: Apatinib Alleviates the Unique Adverse Events Induced by Camrelizumab in non-Small Cell Lung Cancer","volume":"15","author":"Li","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jtho.2020.10.002","article-title":"Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial","volume":"16","author":"Fan","year":"2021","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-2571","article-title":"Camrelizumab in Combination With Apatinib in Patients With Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-Label, Phase II Trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res  Off J Am Assoc Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01920","article-title":"Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial","volume":"38","author":"Lan","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.784861\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T05:24:35Z","timestamp":1641446675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.784861\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2021.784861"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.784861","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,6]]},"article-number":"784861"}}